TY - JOUR
T1 - Recommendations to promote equity, diversity and inclusion in decentralized clinical trials
AU - Aiyegbusi, Olalekan Lee
AU - Cruz Rivera, Samantha
AU - Kamudoni, Paul
AU - Anderson, Nicola
AU - Collis, Philip
AU - Denniston, Alastair K.
AU - Harding, Rosie
AU - Hughes, Sarah E.
AU - Khunti, Kamlesh K
AU - Kotecha, Dipak
AU - Krumholz, Harlan
AU - Liu, Xiaoxuan
AU - McMullan, Christel
AU - Molony-Oates, Barbara
AU - Monteiro, Joao
AU - Myles, Puja
AU - Rantell, Khadija Rerhou
AU - Soltys, Katherine
AU - Verdi, Ravinder
AU - Wilson, Roger
AU - Calvert, Melanie J.
PY - 2024/10/29
Y1 - 2024/10/29
N2 - Decentralized clinical trials involving the use of digital tools to facilitate remote research are gaining momentum. The rapid advancements in digital technologies have supported the adoption of these trials. These innovations facilitate virtual interactions between clinical trial teams and participants by making it easier to collect, transfer, and store electronic data. Whilst some studies demonstrate the potential for these approaches to reduce barriers to clinical trial participation, they are associated with several challenges which may create or worsen existing health inequalities and limit the generalizability of trial results. Here, we review the potential for digitally enabled and decentralized clinical trials to enhance clinical trial participation in an equitable manner. We describe the key barriers individuals from underserved groups may face, and provide recommendations to promote equity, diversity, and inclusion.
AB - Decentralized clinical trials involving the use of digital tools to facilitate remote research are gaining momentum. The rapid advancements in digital technologies have supported the adoption of these trials. These innovations facilitate virtual interactions between clinical trial teams and participants by making it easier to collect, transfer, and store electronic data. Whilst some studies demonstrate the potential for these approaches to reduce barriers to clinical trial participation, they are associated with several challenges which may create or worsen existing health inequalities and limit the generalizability of trial results. Here, we review the potential for digitally enabled and decentralized clinical trials to enhance clinical trial participation in an equitable manner. We describe the key barriers individuals from underserved groups may face, and provide recommendations to promote equity, diversity, and inclusion.
U2 - 10.1038/s41591-024-03323-w
DO - 10.1038/s41591-024-03323-w
M3 - Article
SN - 1078-8956
JO - Nature Medicine
JF - Nature Medicine
ER -